U.S., April 23 -- ClinicalTrials.gov registry received information related to the study (NCT07544589) titled 'A Phase 1 Study Evaluating DISP-10 in Participants With Advanced Gastrointestinal Cancers' on April 07.
Brief Summary: This is a Phase 1, multicenter, open-label study of DISP-10, a combination therapy consisting of DV-10 (adenovirus) and idecabtagene vicleucel (ide-cel, BCMA-directed chimeric antigen receptor [CAR] T), in adult participants with advanced gastrointestinal (GI) cancers.
The study will consist of 2 parts: dose-escalation (Part 1) and dose-expansion (Part 2). Part 1 of the study will evaluate the safety and tolerability of increasing dose levels of DISP-10 to establish the recommended dose for expansion (RDE); Part 2...